131 related articles for article (PubMed ID: 37649096)
1. FOXO1 Inhibition Generates Potent Nonactivated CAR T Cells against Solid Tumors.
Marchais M; Simula L; Phayanouvong M; Mami-Chouaib F; Bismuth G; Decroocq J; Bouscary D; Dutrieux J; Mangeney M
Cancer Immunol Res; 2023 Nov; 11(11):1508-1523. PubMed ID: 37649096
[TBL] [Abstract][Full Text] [Related]
2. FOXO1 is a master regulator of memory programming in CAR T cells.
Doan AE; Mueller KP; Chen AY; Rouin GT; Chen Y; Daniel B; Lattin J; Markovska M; Mozarsky B; Arias-Umana J; Hapke R; Jung IY; Wang A; Xu P; Klysz D; Zuern G; Bashti M; Quinn PJ; Miao Z; Sandor K; Zhang W; Chen GM; Ryu F; Logun M; Hall J; Tan K; Grupp SA; McClory SE; Lareau CA; Fraietta JA; Sotillo E; Satpathy AT; Mackall CL; Weber EW
Nature; 2024 May; 629(8010):211-218. PubMed ID: 38600391
[TBL] [Abstract][Full Text] [Related]
3. FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy.
Chan JD; Scheffler CM; Munoz I; Sek K; Lee JN; Huang YK; Yap KM; Saw NYL; Li J; Chen AXY; Chan CW; Derrick EB; Todd KL; Tong J; Dunbar PA; Li J; Hoang TX; de Menezes MN; Petley EV; Kim JS; Nguyen D; Leung PSK; So J; Deguit C; Zhu J; House IG; Kats LM; Scott AM; Solomon BJ; Harrison SJ; Oliaro J; Parish IA; Quinn KM; Neeson PJ; Slaney CY; Lai J; Beavis PA; Darcy PK
Nature; 2024 May; 629(8010):201-210. PubMed ID: 38600376
[TBL] [Abstract][Full Text] [Related]
4. CAR T Cells Releasing IL-18 Convert to T-Bet
Chmielewski M; Abken H
Cell Rep; 2017 Dec; 21(11):3205-3219. PubMed ID: 29241547
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy.
Klebanoff CA; Crompton JG; Leonardi AJ; Yamamoto TN; Chandran SS; Eil RL; Sukumar M; Vodnala SK; Hu J; Ji Y; Clever D; Black MA; Gurusamy D; Kruhlak MJ; Jin P; Stroncek DF; Gattinoni L; Feldman SA; Restifo NP
JCI Insight; 2017 Dec; 2(23):. PubMed ID: 29212954
[TBL] [Abstract][Full Text] [Related]
6. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
Front Immunol; 2021; 12():665970. PubMed ID: 34475869
[TBL] [Abstract][Full Text] [Related]
7. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
[TBL] [Abstract][Full Text] [Related]
8. Enhanced CAR-T activity against established tumors by polarizing human T cells to secrete interleukin-9.
Liu L; Bi E; Ma X; Xiong W; Qian J; Ye L; Su P; Wang Q; Xiao L; Yang M; Lu Y; Yi Q
Nat Commun; 2020 Nov; 11(1):5902. PubMed ID: 33214555
[TBL] [Abstract][Full Text] [Related]
9. Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.
Murad JM; Baumeister SH; Werner L; Daley H; Trébéden-Negre H; Reder J; Sentman CL; Gilham D; Lehmann F; Snykers S; Sentman ML; Wade T; Schmucker A; Fanger MW; Dranoff G; Ritz J; Nikiforow S
Cytotherapy; 2018 Jul; 20(7):952-963. PubMed ID: 30180944
[TBL] [Abstract][Full Text] [Related]
10. Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy.
Urak R; Walter M; Lim L; Wong CW; Budde LE; Thomas S; Forman SJ; Wang X
J Immunother Cancer; 2017; 5():26. PubMed ID: 28331616
[TBL] [Abstract][Full Text] [Related]
11.
Suematsu M; Yagyu S; Nagao N; Kubota S; Shimizu Y; Tanaka M; Nakazawa Y; Imamura T
Front Immunol; 2022; 13():770132. PubMed ID: 35154098
[TBL] [Abstract][Full Text] [Related]
12. Point-Of-Care CAR T-Cell Production (ARI-0001) Using a Closed Semi-automatic Bioreactor: Experience From an Academic Phase I Clinical Trial.
Castella M; Caballero-Baños M; Ortiz-Maldonado V; González-Navarro EA; Suñé G; Antoñana-Vidósola A; Boronat A; Marzal B; Millán L; Martín-Antonio B; Cid J; Lozano M; García E; Tabera J; Trias E; Perpiña U; Canals JM; Baumann T; Benítez-Ribas D; Campo E; Yagüe J; Urbano-Ispizua Á; Rives S; Delgado J; Juan M
Front Immunol; 2020; 11():482. PubMed ID: 32528460
[TBL] [Abstract][Full Text] [Related]
13. Optimization of manufacturing conditions for chimeric antigen receptor T cells to favor cells with a central memory phenotype.
Gargett T; Truong N; Ebert LM; Yu W; Brown MP
Cytotherapy; 2019 Jun; 21(6):593-602. PubMed ID: 30975603
[TBL] [Abstract][Full Text] [Related]
14. Disrupting N-glycan expression on tumor cells boosts chimeric antigen receptor T cell efficacy against solid malignancies.
Greco B; Malacarne V; De Girardi F; Scotti GM; Manfredi F; Angelino E; Sirini C; Camisa B; Falcone L; Moresco MA; Paolella K; Di Bono M; Norata R; Sanvito F; Arcangeli S; Doglioni C; Ciceri F; Bonini C; Graziani A; Bondanza A; Casucci M
Sci Transl Med; 2022 Jan; 14(628):eabg3072. PubMed ID: 35044789
[TBL] [Abstract][Full Text] [Related]
15. Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 mice.
Chen M; Sun R; Shi B; Wang Y; Di S; Luo H; Sun Y; Li Z; Zhou M; Jiang H
Biomed Pharmacother; 2019 May; 113():108734. PubMed ID: 30849636
[TBL] [Abstract][Full Text] [Related]
16. Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy.
Ghassemi S; Milone MC
J Vis Exp; 2019 Dec; (154):. PubMed ID: 31904011
[TBL] [Abstract][Full Text] [Related]
17. CAR T Cells Redirected to CD44v6 Control Tumor Growth in Lung and Ovary Adenocarcinoma Bearing Mice.
Porcellini S; Asperti C; Corna S; Cicoria E; Valtolina V; Stornaiuolo A; Valentinis B; Bordignon C; Traversari C
Front Immunol; 2020; 11():99. PubMed ID: 32117253
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic activity of anti-mucin 1 chimeric antigen receptor T cells expressing PD-1-CD28 switch receptor against cholangiocarcinoma cells.
Supimon K; Sangsuwannukul T; Sujjitjoon J; Chieochansin T; Junking M; Yenchitsomanus PT
Cytotherapy; 2023 Feb; 25(2):148-161. PubMed ID: 36396553
[TBL] [Abstract][Full Text] [Related]
19. Functional characterization and development of novel human kinase insert domain receptor chimeric antigen receptor T-cells for immunotherapy of non-small cell lung cancer.
Zhong M; Chalbatani GM; Deng M; Li Q; Gharagouzloo E; Hamblin MR; Suarez ER; Hu L; Wang D
Eur J Pharm Sci; 2023 Jan; 180():106331. PubMed ID: 36384203
[TBL] [Abstract][Full Text] [Related]
20. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy.
Zhang Z; Jiang J; Wu X; Zhang M; Luo D; Zhang R; Li S; He Y; Bian H; Chen Z
Front Med; 2019 Feb; 13(1):57-68. PubMed ID: 30721445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
